MENU

INCR Stock Intercure (INCR, $1.71) Moving Average Convergence Divergence (MACD) Histogram turned negative on October 14, 2024

A.I.dvisor
at Tickeron.com
10/15/24
Loading...
INCR - Intercure Ltd
MACD signal
Bearish Trend
Odds of DOWN Trend
Tickeron
MACD signal
Price: $1.71
Daily change: -$0.12 (-6.56%)
Daily volume: 44.6K
Industry: Pharmaceuticals: Other
This is a Bearish indicator signaling INCR's price could decline from here. Traders may explore shorting the stock or put options. A.I. dvisor identified 53 similar cases where INCR's MACD histogram became negative, and of them led to successful outcomes. Odds of Success:

INCR sees its 50-day moving average cross bearishly below its 200-day moving average

The 50-day moving average for INCR moved below the 200-day moving average on September 23, 2024. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 08, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on INCR as a result. In of 114 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for INCR turned negative on October 14, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where INCR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for INCR entered a downward trend on October 02, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where INCR's RSI Oscillator exited the oversold zone, of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 66 cases where INCR's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where INCR advanced for three days, in of 188 cases, the price rose further within the following month. The odds of a continued upward trend are .

INCR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. INCR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.928) is normal, around the industry mean (56.825). P/E Ratio (22.519) is within average values for comparable stocks, (89.935). INCR's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.890). Dividend Yield (0.000) settles around the average of (0.122) among similar stocks. P/S Ratio (1.145) is also within normal values, averaging (18.882).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INCR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.

View a ticker or compare two or three
INCR
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of outsourced clinical development and commercialization services to biopharmaceutical companies

Industry PharmaceuticalsOther

Profile
Fundamentals
Details
Industry
Servicestothe Health Industry
Address
85 Medinat ha-Yehudim Street
Phone
+972 774605012
Employees
370
Web
https://www.intercure.co